AnaptysBio, Inc., a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases, reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company generated collaboration revenue of $234.6 million, a substantial increase from $91.3 million in the previous year, primarily driven by milestone payments and royalties from its collaboration with GSK for the PD-1 antagonist, Jemperli. The net loss for the year was $13.2 million, a notable improvement compared to a loss of $145.2 million in 2024, reflecting a decrease in research and development expenses and an increase in collaboration revenue.
The company is currently advancing its clinical pipeline, which includes rosnilimab, a selective T cell depleter that has completed a Phase 2b trial for rheumatoid arthritis, and ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis. AnaptysBio also announced plans to separate its operations into two independent publicly traded companies, with the separation expected to be completed in the second quarter of 2026. This strategic move aims to enhance focus on its clinical-stage biotechnology efforts while managing the financial collaboration for Jemperli and imsidolimab separately.
Operationally, AnaptysBio reported a decrease in research and development expenses to $136.0 million from $163.8 million in 2024, attributed to reduced clinical expenses and outside services. The company’s employee headcount stood at 104 as of January 31, 2026, with a significant portion engaged in research and development activities. The filing also highlighted the company’s reliance on third-party manufacturers for clinical supplies, emphasizing the potential risks associated with supply chain disruptions.
Looking ahead, AnaptysBio's management expressed optimism about the future, citing the potential for continued revenue growth from collaboration agreements and the advancement of its clinical pipeline. However, the company acknowledged the inherent risks in drug development, including regulatory approvals and market acceptance, which could impact its financial performance. The company’s ability to sustain operations and fund future development will depend on its success in navigating these challenges and securing additional financing as needed.
About ANAPTYSBIO, INC
AnaptysBio, Inc. is a clinical-stage biotechnology company specializing in innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead product, rosnilimab, targets PD-1+ T cells and is in Phase 2b trials for rheumatoid arthritis and ulcerative colitis. With a focus on underserved patient populations, AnaptysBio aims to leverage its antibody pipeline and collaborations, including with GlaxoSmithKline, to address significant market opportunities in immunology.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.